Core Insights - AC Immune SA announced the peer-reviewed publication of results from the Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau, in eBioMedicine [2][3] - The trial demonstrated that ACI-35.030 generated a rapid and durable polyclonal response against pathological Tau without clinically relevant safety issues [2][4] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's disease [12] - The company utilizes its proprietary SupraAntigen® technology to develop its immunotherapies, which are designed to elicit strong immune responses against misfolded proteins [12][8] Trial Results - ACI-35.030 showed a rapid and potent polyclonal antibody response against pathological forms of Tau after the first dose, with 94% to 100% response rates maintained until week 74 in high-dose cohorts [4][5] - The trial included two formulations, ACI-35.030 and JACI-35.054, with ACI-35.030 requiring only one injection to induce anti-pTau IgG antibody titers in all participants [5][6] - ACI-35.030 is currently advancing in the Phase 2b ReTain trial, which aims to assess its potential to modify the disease in preclinical Alzheimer's disease [6][9] Future Developments - The ongoing Phase 2b ReTain trial will include approximately 500 participants and aims to evaluate the cognitive effects of ACI-35.030 over a maximum of four years [10][11] - The primary endpoint of the trial is to measure cognitive decline using the Preclinical AD Cognitive Composite 5 (PACC-5) score, while secondary endpoints will assess the impact on Tau pathology [11]

Core Insights - AC Immune SA is set to present its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) in Vienna, Austria, from April 1 to 5, 2025, focusing on active immunotherapies for neurodegenerative diseases [1][4] Group 1: Upcoming Presentations - The company will host an industry symposium on April 2, 2025, featuring key opinion leaders discussing advances in clinical development of active immunotherapies [2] - Presentations will cover topics such as disease modification in Parkinson's disease, targeting alpha-synuclein, and precision prevention strategies for Alzheimer's disease [2][3] - The symposium will include a Q&A session and a replay will be available on AC Immune's website [2] Group 2: Research and Development Highlights - AC Immune's pipeline includes Morphomer® small molecules targeting Tau for Alzheimer's disease treatment, with a presentation scheduled for April 5, 2025 [3] - The company is developing Morphomer-antibody drug conjugates, a new class of drugs for neurodegenerative diseases [3] - Research on therapeutic small molecules targeting alpha-synuclein aggregation will also be presented [3] Group 3: Company Overview - AC Immune is a clinical-stage biopharmaceutical company focused on precision prevention for neurodegenerative diseases, leveraging its two technology platforms, SupraAntigen® and Morphomer® [6] - The company has a diversified pipeline featuring candidates in Phase 2 and Phase 3 development, with significant strategic partnerships leading to over $4.5 billion in potential milestone payments and royalties [6]